PIN18 - COST-CONSEQUENCES ANALYSIS OF COFORMULATED ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE IN PATIENT POPULATIONS WITH DIFFERING RISK PROFILES. - Gallant, J.; Altice, F.; Folse, H.J. (Value in Health, 2016)